Core Viewpoint - The stock price of 加科思-B (01167) increased by 6.17% to HKD 8.09, with a trading volume of HKD 17.6587 million, following the announcement of a capital increase and equity transfer agreement [1][5] Group 1: Financial Developments - 加科思's subsidiary, 北京加科思, received a first payment of RMB 125 million from 海松资本 as part of the capital increase and equity transfer agreement, enhancing the group's cash reserves [1][5] - The influx of funds is expected to support the development of innovative cancer therapy pipelines [1][5] Group 2: Clinical Research Achievements - 加科思 announced that the clinical I/IIa study results of its self-developed KRAS G12C inhibitor, glecirasib, in combination with SHP2 inhibitor JAB-3312, were published in the prestigious medical journal, The Lancet Respiratory Medicine, which has an impact factor of 32.8 [1][5] - This publication marks the first systematic clinical data on the combination of KRAS G12C and SHP2 dual oral small molecule therapy to be featured in such a high-profile journal [1][5]

Core Viewpoint - The stock of Gossamer Bio, Inc. (01167) has seen a significant increase, rising over 6% during trading, with a current price of HKD 8.04 and a trading volume of HKD 8.1525 million. The company has received a substantial payment that enhances its cash reserves and supports its ongoing research in innovative cancer therapies [1]. Group 1 - Gossamer Bio's subsidiary, Beijing Gossamer, has received an initial payment of RMB 125 million from Haisong Capital, which bolsters the group's cash reserves [1]. - The receipt of this payment is expected to facilitate the advancement of the company's pipeline for innovative cancer therapies [1]. Group 2 - Gossamer Bio announced the publication of clinical I/IIa study results for its self-developed KRAS G12C inhibitor, Glecirasib, in combination with SHP2 inhibitor JAB-3312 (Sitneprotafib) in the prestigious medical journal, The Lancet Respiratory Medicine, which has an impact factor of 32.8 [1]. - This publication marks the first time systematic clinical data on the combination of KRAS G12C and SHP2 oral small molecule therapies has been featured in such a reputable journal [1].

智通财经APP获悉，加科思-B(01167)盘中涨超6%，截至发稿，涨5.51%，报8.04港元，成交额815.25万 港元。 消息面上，加科思发布公告，公司的附属公司北京加科思已收到海松资本支付的人民币1.25亿元的首付 款。该首付款的到账，进一步充盈了集团的现金储备，也将为集团后续创新肿瘤疗法管线研发的推进提 供助力。 此外，加科思近日宣布，公司自研的KRAS G12C抑制剂戈来雷塞(glecirasib)联合SHP2抑制剂JAB- 3312(sitneprotafib)的临床I/IIa期研究成果正式发表于国际顶级医学期刊《柳叶刀呼吸医学》(影响因子 32.8)。这是全球首次有KRAS G12C与SHP2双口服小分子联合疗法的系统性临床资料登上该权威期刊。 ...

Core Viewpoint - Apollomics Inc. is a clinical-stage biotechnology company focused on developing innovative cancer therapies, particularly for patients with limited treatment options, and is currently advancing its lead candidate APL-101 (vebreltinib) through global clinical trials [1][3]. Group 1: Company Overview - Apollomics has 9 drug candidates in its pipeline, with 6 in clinical development targeting challenging cancers such as lung cancer and brain cancer [1]. - The company employs a strategy that combines targeted therapies, immuno-oncology, and innovative mechanisms of action to overcome resistance and achieve clinically meaningful efficacy [1]. Group 2: Recent Developments - On August 28, 2025, Apollomics announced plans to terminate all clinical trial activities related to APL-101 due to financial issues and sought shareholder approval for liquidation [2]. - Following a PIPE investment of $4.1 million on September 3, 2025, the company appointed a new board and management team, including Howard Chen as CEO and Alex Chen as COO [2]. Group 3: Clinical Trials and Future Plans - After securing additional funding and a new management team, Apollomics canceled its liquidation plans and will continue its existing operations, including the global development of APL-101 [3]. - The company is committed to completing the SPARTA clinical trials for APL-101, which are crucial for maximizing its therapeutic potential across various tumor types and supporting regulatory submissions in major markets [4]. - Apollomics plans to leverage its partnerships in China to advance regulatory submissions for APL-101 in emerging markets outside of Southeast Asia and the Middle East [4]. Group 4: Workforce and Operations - Apollomics currently has 12 full-time employees, with plans to increase the workforce to 15 by October 31, 2025, while also reducing staff in mainland China and reallocating resources to the U.S. and Taiwan [4].